Pluri (NASDAQ:PLUR) Shares Down 12.7% – What’s Next?

Shares of Pluri Inc. (NASDAQ:PLUR) traded down 12.7% on Thursday . The company traded as low as $3.04 and last traded at $3.09. 121,244 shares traded hands during mid-day trading, an increase of 136% from the average session volume of 51,287 shares. The stock had previously closed at $3.54.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pluri in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $12.00.

Pluri Stock Performance

The company has a quick ratio of 0.53, a current ratio of 0.53 and a debt-to-equity ratio of 51.65. The stock has a market cap of $28.49 million, a price-to-earnings ratio of -0.65 and a beta of 0.58. The stock’s fifty day moving average is $3.82 and its 200-day moving average is $4.52.

Pluri (NASDAQ:PLUR) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.65) earnings per share for the quarter. Pluri had a negative return on equity of 4,191.91% and a negative net margin of 1,708.71%.The firm had revenue of $0.32 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC purchased a new position in shares of Pluri Inc. (NASDAQ:PLUR) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri at the end of the most recent reporting period. 16.59% of the stock is owned by institutional investors.

About Pluri

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.